PUBLIC COMPANY
save$FBRXForte Biosciences, Inc.
$FBRX76.990.00%Dallas, TX, USupdated 1mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
- phase1A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
- phase1A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
- phase2Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
🐶 Hiring Signal
News
- Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drugThe deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.biopharma_dive · 2mo ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2BArgenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases. The Belgian-Dutch pharma said Monday it will pay $…endpoints · 2mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that